TY - JOUR
T1 - Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir
T2 - Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315
AU - Kuritzkes, Daniel R.
AU - Sevin, Anne
AU - Young, Benjamin
AU - Bakhtiari, Minoo
AU - Wu, Hulin
AU - St. Clair, Marty
AU - Connick, Elizabeth
AU - Landay, Alan
AU - Spritzler, John
AU - Kessler, Harold
AU - Lederman, Michael M.
PY - 2000
Y1 - 2000
N2 - The effect of baseline drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in zidovudine- experienced persons infected with human immunodeficiency virus type 1 (HIV- 1). Presence of the K70R mutation was associated with significantly higher plasma HIV-1 RNA levels at baseline. However, presence of resistance mutations did not affect the increase in plasma HIV-1 RNA during a 5-week drug washout, nor was there any effect on first-phase virus decay rates after initiation of therapy or on the probability of having plasma HIV-1 RNA levels <100 copies/mL at week 48. Polymorphisms at protease codons 10, 36, and 71 were associated with significantly faster second-phase decay rates. Suppression of plasma HIV-1 RNA despite presence of zidovudine resistance mutations implies that the presence of these mutations does not preclude a durable response to treatment with a potent 3-drug regimen.
AB - The effect of baseline drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in zidovudine- experienced persons infected with human immunodeficiency virus type 1 (HIV- 1). Presence of the K70R mutation was associated with significantly higher plasma HIV-1 RNA levels at baseline. However, presence of resistance mutations did not affect the increase in plasma HIV-1 RNA during a 5-week drug washout, nor was there any effect on first-phase virus decay rates after initiation of therapy or on the probability of having plasma HIV-1 RNA levels <100 copies/mL at week 48. Polymorphisms at protease codons 10, 36, and 71 were associated with significantly faster second-phase decay rates. Suppression of plasma HIV-1 RNA despite presence of zidovudine resistance mutations implies that the presence of these mutations does not preclude a durable response to treatment with a potent 3-drug regimen.
UR - http://www.scopus.com/inward/record.url?scp=0034006789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034006789&partnerID=8YFLogxK
U2 - 10.1086/315244
DO - 10.1086/315244
M3 - Article
C2 - 10669331
AN - SCOPUS:0034006789
SN - 0022-1899
VL - 181
SP - 491
EP - 497
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -